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Background: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of innate immune cells
with a granulocyte-like or monocyte-like phenotype and a unique ability to suppress T-cell responses. MDSCs have
been shown to accumulate in cancer patients, but recent studies suggest that these cells are also present in
humans and animals suffering from autoimmune diseases. We previously identified MDSCs in the synovial fluid (SF)
of mice with experimental autoimmune arthritis. The goal of the present study was to identify MDSCs in the SF of
patients with rheumatoid arthritis (RA).
Methods: RA SF cells were studied by flow cytometry using antibodies to MDSC cell surface markers as well as by
analysis of cell morphology. The suppressor activity of RA SF cells toward autologous peripheral blood T cells was
determined ex vivo. We employed both antigen-nonspecific (anti-CD3/CD28 antibodies) and antigen-specific
(allogeneic cells) induction systems to test the effects of RA SF cells on the proliferation of autologous T cells.
Results: SF from RA patients contained MDSC-like cells, the majority of which showed granulocyte (neutrophil)-like
phenotype and morphology. RA SF cells significantly suppressed the proliferation of anti-CD3/CD28-stimulated
autologous T cells upon co-culture. When compared side by side, RA SF cells had a more profound inhibitory
effect on the alloantigen-induced than the anti-CD3/CD28-induced proliferation of autologous T cells.
Conclusion: MDSCs are present among RA SF cells that are commonly regarded as inflammatory neutrophils.
Our results suggest that the presence of neutrophil-like MDSCs in the SF is likely beneficial, as these cells have
the ability to limit the expansion of joint-infiltrating T cells in RA.
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Rheumatoid arthritis (RA) is an autoimmune disease
characterized by inflammatory destruction of peripheral
joints [1]. The involvement of autoreactive T cells in RA
pathogenesis is supported by a genetic linkage between
disease susceptibility and certain MHC class II (HLA-
DR) molecules expressed by antigen-presenting cells [2],
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unless otherwise stated.(autoAgs) [3]. Moreover, the presence of isotype-switched
antibodies (Abs) against self IgG (i.e., rheumatoid factor)
as well as against native and citrullinated self proteins in
the majority of RA patients [4] is likely the result of help
to Ab-producing B cells provided by autoreactive T helper
(Th) cells [5]. T cells, belonging mainly to the Th1 and
Th17 subsets, are also present in the rheumatoid joint and
are believed to contribute greatly to local tissue damage
[1,6]. However, granulocytes (innate immune cells) consti-
tute the major population of RA synovial fluid (SF) cells
[1,7]. Although SF granulocytes (mainly neutrophils) and
monocytes can inflict considerable damage to joint struc-
tures through the release of proteolytic enzymes, pro-
inflammatory cytokines, and other noxious substances [1],td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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limiting the local expansion of these T cells.
Myeloid-derived suppressor cells (MDSCs) are cells of
the innate immune system with a remarkable ability to
suppress T-cell responses [8]. MDSCs are characterized
by an “immature” phenotype on the basis of expression
of CD33 (also present in myeloid precursors), and the
absence or very low levels of HLA-DR [9,10]. MDSCs
also express the common myeloid marker CD11b, the α
chain of the CD11b/CD18 leukocyte integrin heterodi-
mer (also termed αMβ2 integrin or Mac-1), which is
found mainly on granulocytes, monocytes, and macro-
phages [11]. Indeed, MDSCs can be roughly categorized
as granulocytic (CD15+ or CD66b+ cells showing poly-
morphonuclear morphology) and monocytic (CD14+ cells
showing mononuclear morphology) subsets [8]. However,
MDSCs belonging to these subsets (particularly granulo-
cytic cells) exhibit a high degree of heterogeneity re-
garding nuclear morphology and the potency and the
mechanism of immune suppression [12].
MDSCs were first identified in cancer patients and were
shown to accumulate both in the vicinity of tumors and in
peripheral blood [10,13]. The survival and suppressive
function of MDSCs are supported by tumor-produced
myelopoietic growth factors including granulocyte macro-
phage colony-stimulating factor (GM-CSF), interleukin
(IL)-6, granulocyte colony-stimulating factor (G-CSF) and
others [14,15], but some of these factors might also be
produced at inflammatory sites [16-18].
Recent studies suggest that MDSCs are present at in-
creased frequencies in the peripheral blood of patients
with autoimmune diseases such as multiple sclerosis
(MS) [19] and RA [20] as compared with healthy indi-
viduals. We previously identified MDSCs with a pre-
dominantly granulocytic phenotype in the SF of mice
with proteoglycan-induced arthritis (PGIA, an autoimmune
mouse model of RA) [21]. In this pilot study, we show that
MDSCs are also present in the SF of RA patients.
Methods
Patients
Eleven RA patients undergoing therapeutic joint fluid
aspiration at two clinics (Section of Rheumatology of the
Department of Internal Medicine, and Rheumatology
Associates) at Rush University Medical Center partici-
pated in the study. Informed consent was obtained from
each of the participants. The 11 RA patients all donated
SF, and 9 of them also donated blood. The specimens
(SF and peripheral blood from RA patients and periph-
eral blood from a healthy volunteer) were collected through
the Knee Injury and Arthritis Repository Study approved by
the Institutional Review Board of Rush University Medical
Center (Chicago, IL, USA). All patients had established RA
according to the 2010 ACR/EULAR classification criteria[22] and substantial joint effusions requiring therapeutic as-
piration. The mean age of the RA patients (9 females and 2
males) was 50.3 years (age range: 33–61 years).
Analysis of cell surface marker expression and
morphology of RA SF cells
Cells from the SF were pelleted by centrifugation (1000 rpm
for 10 min at 4°C) and washed with sterile culture medium.
Most of the SF samples had visible fibrin clots (formed in
the syringe after joint aspiration). In these cases, clots and
large cell aggregates were removed by passing the cell sus-
pension through sterile 70 μm pore-size cell restrainer filters
(BD Biosciences, San Diego, CA, USA). The cells were then
counted and used for phenotypic, morphologic, and func-
tional analyses without further separation. The reason for
not separating MDSCs (which involves antibody-based posi-
tive selection for CD11b+ myeloid cells followed by sorting
for CD33+HLA-DR− MDSC-like cells) was that antibodies
against CD11b (the α chain of the Mac-1 integrin, present
in the majority of RA SF cells [1,7]) had been reported to
interfere with the function of myeloid cells including inhib-
ition of T-cell responses [11,23]. An aliquot of SF cells was
immunostained and processed for flow cytometry. Before
immunostaining, Fc receptors were blocked with purified
human FcR inhibitor (eBioscience, San Diego, CA, USA)
and then the cells were stained with fluorochrome-labeled
monoclonal Abs (mAbs) against the following surface
markers: CD11b, CD33, HLA-DR, CD14, and CD15
(from eBioscience or BioLegend, San Diego, CA, USA).
Flow cytometry was performed using a BD FACS Canto II
instrument, and data were analyzed with FACS Diva soft-
ware (BD Flow Cytometry Systems, San Jose, CA, USA).
For analysis of cell morphology, an aliquot of SF cells was
spun onto glass slides, air dried, and stained with Wright-
Giemsa solution (Sigma-Aldrich, St. Louis, MO, USA).
Cytospin preparations were viewed and photographed
using a Nikon Microphot light microscope (Nikon,
Melville, NY, USA) equipped with a digital CCD camera
(Coolsnap; RS Photometrics, Tucson, AR, USA).
Cell isolation from human peripheral blood and
suppression assays
Venous blood was collected in heparin-containing tubes,
and peripheral blood mononuclear cells (PBMCs) were
isolated on a Ficoll density gradient (GE Healthcare Life
Sciences, Piscataway, NJ, USA) according to a standard
protocol. After extensive washing, PBMCs were sus-
pended in Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS; Hyclone, Logan,
UT, USA). Viability (usually >95%) and cell counts for
PBMCs as well as for SF cells were determined prior to
culture. PBMCs were seeded in 96-well plates previously
coated with anti-human-CD3 mAb (1 μg/well; BioLegend)
at a density of 1 × 105 cells per well in DMEM containing
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arated) SF cells at a ratio of 1:1. Background controls
included PBMCs cultured in uncoated wells, and SF
cells seeded in anti-CD3-coated wells. Anti-CD28 mAb
(1 μg/well; BioLegend) was added in solution to cells
in all anti-CD3-coated wells. The cells (4–6 wells/con-
dition) were cultured for 4 days, and pulsed with [3H]
thymidine (Perkin Elmer, Waltham, MA, USA) at 1 μCi/
well for the last 18 hours of culture. Isotope incorporation
(counts per minute: cpm) into dividing cells was measured
in a MicroBeta scintillation counter (Perkin Elmer). As
the actual cpm values varied from patient to patient, we
calculated the ratios of T-cell proliferation in the presence
of SF cells relative to positive control (i.e., in the absence
of SF cells) after background correction.
We obtained sufficient numbers of both PBMCs and SF
cells from 3 patients (RA #7, 8, and 9) to compare the effects
of SF cells on anti-CD3/CD28-induced (non Ag-specific)
and alloreactive (Ag-specific) proliferation of T cells side by
side. To induce Ag-specific (allogeneic mixed leukocyte)
response, RA PBMCs were co-cultured with allogeneic
PBMCs from a HLA-mismatched healthy donor in the ab-
sence or presence of autologous SF cells at a RA PBMC:nor-
mal PBMC:RA SF cell ratio of 1:1:1. The allogeneic cells
were treated for 30 min with Mitomycin C (40 μg/ml;
Sigma-Aldrich) prior to co-culture to inhibit cell division,
and proliferation of autologous (RA) T cells was determined
on day 5 on the basis of [3H]thymidine incorporation. In this
case, cmp values of Mitomycin C-treated allogeneic PBMCs
(cultured alone) were included in the background controls.
Isotope incorporation (cpm values) by the cells of this
group of 3 RA patients was reasonably similar when the
cells were stimulated with anti-CD3/28 or with allogen-
eic PBMCs or cultured alone. This allowed us to com-
pare the background-corrected cpm values as well as the
proliferation ratios under the two different conditions of
in vitro stimulation.
Statistical analysis
Descriptive statistics was employed to determine the
means ± SEM and 95% confidence intervals (95% CI). The
parametric paired t test and the nonparametric Wilcoxon
matched-pairs signed rank test were used (as appropriate)
to detect statistically significant (p < 0.05) differences in
the cpm values and in the proliferation ratios of RA
PBMCs under the different culture conditions. Statistical
analysis of data was performed using GraphPad Prism 6
program (GraphPad Software, La Jolla, CA, USA).
Results
Cells with phenotype and morphology resembling MDSCs
are present in the SF of RA patients
Screening for MDSC-like cells was carried out by flow
cytometry using SF samples collected from 11 RApatients. We employed a combination of mAbs to MDSC
cell surface markers including the common myeloid marker
CD11b, the “immature” myeloid cell marker CD33, MHC II
(HLA-DR), the monocytic MDSC subset marker CD14, and
the granulocytic subset marker CD15 [8-10]. As demon-
strated by a representative sample, CD11b+CD33+HLA-
DRlo/-CD14−CD15+ granulocytic MDSC-like cells were the
predominant cell type in RA SF, but a small population
of the CD11b+CD33+HLA-DRlo/-CD14+CD15− mono-
cytic subset was also present (Figure 1A). MDSC-like
cells constituted ~85% of all SF cells (Figure 1B, left-side
graph) and ~95% of these MDSC-like cells belonged to
the granulocytic subset (Figure 1B, first bar in the right-
side graph) in the samples of the 11 RA patients tested.
Despite very similar cell surface marker expression profile
in all RA SF samples (Figure 1A-B), the nuclear morph-
ology of the cells varied among the patients, although the
dominance of the polymorphonuclear (neutrophil-like)
granulocytic subset was evident (Figure 1C).
RA SF cells significantly suppress the anti-CD3/CD28-induced
proliferation of autologous T cells
Lechner et al. [24] reported that monocytic MDSCs, gen-
erated in vitro from human PBMCs in the presence of GM-
CSF and IL-6, were able to suppress the anti-CD3/CD28-in-
duced proliferation of autologous T cells. To determine
whether the MDSC-like cells that we identified in RA SF, in-
deed, had suppressive properties, we stimulated T cells
(present in PBMC) with anti-CD3/CD28 mAbs in the ab-
sence and presence of SF cells from the same patients. Anti-
CD3/CD28-stimulated Tcells in PBMC proliferated less well
in the presence than in the absence of autologous SF cells as
indicated by the difference in total [3H]thymidine incorpor-
ation (Figure 2A, condition “a” versus condition “b”). Isotope
incorporation (cpm) by unstimulated PBMCs or anti-CD3/
CD28-treated SF cells (Figure 2A, conditions “c” and “d”, re-
spectively, as background controls) was low, but still detect-
able. We tested PBMCs and SF cells from a total of 9 RA
patients in the same in vitro system, and found that SF cells
from all of these patients suppressed anti-CD3/CD28-in-
duced cell proliferation. Since total isotope incorporation by
PBMCs and PBMC-SF cell co-cultures as well as back-
ground cpm values (conditions “c” and “d”) varied from pa-
tient to patient, we calculated the background-corrected
proliferation ratios for the 9 patients tested. As shown in
Figure 2B, the SF cell-mediated suppression of anti-CD3/
CD28-induced T-cell proliferation was statistically signifi-
cant (p = 0.0039, 95% CI = 0.4682-0.7495).
SF cells from the same RA patients are more potent in
suppressing the Ag-specific than the anti-CD3/CD28-induced
proliferation of autologous T cells
We reported previously that MDSCs present in the SF of
the arthritic joints of mice with PGIA potently suppressed
Figure 1 Presence of cells with myeloid-derived suppressor cell (MDSC)-like phenotype and morphology in synovial fluid (SF) from
rheumatoid arthritis (RA) patients. (A) Flow cytometry profile of RA SF cells using a combination of antibodies against the common myeloid
marker CD11b, the “immature” myeloid cell marker CD33, MHC class II (HLA-DR), the monocytic subset marker CD14, and the granulocytic subset
marker CD15 (gating strategy is indicated by red arrows). The example shown (1 of 11 RA SF samples with similar profiles) demonstrates the
dominance of CD11b+CD33lo/hiHLA-DRlo/-CD14−CD15+ (granulocytic) MDSC-like cells in RA SF. (B) Using the same gating strategy on the 11 RA
SF samples, the mean frequency of MDSC-like myeloid cells was 85.03% (range: 76.1-97.9%) among the SF cells (left-side graph). The granulocytic
subset represented 95.2% (range: 72.9-99.7%) and the monocytic subset represented 1.3% (range: 0.1-5.3%) of the MDSC-like SF cell population
(bars in right-side graph). The data shown are the means ± SEM. (C) The morphology of SF cells in Wright-Giemsa-stained cytospin preparations
from 3 RA patients also indicated the dominance of the polymorphonuclear granulocytic subset, although the shape of the nuclei of these
neutrophil-like cells varied among the patients.
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effective against anti-CD3/CD28-induced proliferation
[21]. In this study, using allogeneic PBMC as a source of
Ag, we directly compared the effects of RA SF cells on the
anti-CD3/CD28-induced versus alloAg-induced prolifera-
tion of autologous T cells obtained from the same patients.
Side-by-side comparison of cell cultures of these RAFigure 2 Suppression of anti-CD3/CD28-induced polyclonal proliferat
Peripheral blood mononuclear cells (PBMC) stimulated with anti-CD3/CD28
“a”) or presence (“b”) of SF cells (SFC) from the same RA patient (RA #3). Ba
Abs (“c”) and SF cells cultured with anti-CD3/CD28 Abs (“d”). The results sh
cpm) by the proliferating cells (6 wells per condition). As the actual cpm va
calculated the proliferation ratio (with background correction) for each RA
control (a - c) was set to 1. (B) As indicated by the proliferation ratios, th
gray bar) was significantly suppressed in the presence of SF cells (black
proliferation ratios (**p < 0.01; Wilcoxon matched-pair signed rank test; n = 9 ppatients (RA #7, 8, 9) demonstrated significant (p = 0.0389)
but moderate activity of SF cells in inhibiting the robust
proliferation of anti-CD3/CD28-stimulated autologous T
cells (Figure 3A), and also significant (p = 0.0087) and more
effective suppression of the Ag-induced (and more modest)
proliferation of the same T cells (Figure 3B). Since the SF
cell populations from the same RA patients exhibitedion of autologous peripheral blood T cells by RA SF cells. (A)
monoclonal antibodies (Abs) were cultured in the absence (condition
ckground controls included PBMCs cultured without anti-CD3/CD28
own are the means ± SEM of isotope incorporation (counts per minute,
lues at all of the listed conditions varied from patient to patient, we
patient using the formula: [b − (c + d)]/(a − c), where the positive
e anti-CD3/CD28-induced proliferation of autologous PBMCs (light
bar). The results shown are the means ± SEM of background-corrected
atients).
Figure 3 Comparison of the suppressive effects of RA SF cells on the anti-CD3/CD28-induced and alloantigen-induced proliferation of
autologous T cells. (A) Isotope incorporation (cpm) by anti-CD3/CD28 Ab-stimulated PBMCs (light blue bar) was moderately, but significantly
reduced in the presence (dark blue bar) of SF cells (SFC) from 3 RA patients (RA #7, 8, 9). (B) Allogeneic PBMC-induced proliferation of
PBMCs from the same 3 patients (orange bar) was greatly reduced in the presence of autologous SF cells (dark red bar). The data shown in
panels A and B are the means ± SEM of background-corrected cpm values (4 wells per condition) (*p < 0.05, **p < 0.01; Paired t test). (C) Comparison of
the ratios of anti-CD3/CD28-induced (dark blue bar) and allogeneic PBMC-induced (dark red bar) proliferation of RA PBMCs in the presence of autologous
SFC in the 3 RA patients (cpm values shown in panels A and B) indicated that SF cells from the same patients were more efficient in suppressing the
allogeneic PBMC-induced than the anti-CD3/CD28-induced proliferation of autologous T cells. The data are the means ± SEM of background-corrected
proliferation ratios (*p < 0.05; Paired t test).
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under the two different culture conditions (Figure 3C),
these results also suggested that inhibition of T-cell prolif-
eration was not simply due to cytotoxic substances re-
leased from degranulating, dying, or apoptotic SF cells
upon culture.
Discussion
MDCSs have been gaining increasing attention in re-
cent years as important modulators of adaptive im-
mune responses in various diseases [8]. In cancer
patients, accumulation of MDSCs around the tumors
as well as at the periphery can be detrimental, as these
cells suppress tumor Ag-specific T cells, thus weaken-
ing anti-tumor immunity [13,25]. On the contrary,
MDSC-mediated suppression of T-cell responses can
be beneficial in pathologic conditions characterized by
the unopposed activation of the adaptive immune sys-
tem such as organ transplant rejection or autoimmune
diseases [12]. Indeed, adoptive transfer of MDSCs in
mouse models of human autoimmune disorders, includ-
ing MS [19], type I diabetes [26], and RA [27], was
followed by reduction in disease severity in the MDSC
recipient mice.
Jiao et al. [20] reported increased frequency of MDSC-
like cells in the blood of patients with RA as compared
with healthy individuals, and also found a negative cor-
relation between the frequencies of circulating MDSC-like
and Th17 cells in RA patients. Unfortunately, MDSC-like
cells were defined by phenotypic marker expression only,
and the suppressor activity of these cells toward T cells
was not tested in that study [20]. For the first time to ourknowledge, here we show that MDSC-like cells are also
present in the SF of RA patients. These cells are true
MDSCs, as they are capable of suppressing the ex vivo in-
duced proliferation of autologous T cells.
With regard to phenotype, we have found that the ma-
jority of MDSC-like RA SF cells belongs the granulocytic
CD11b+CD33+HLA-DRlo/-CD14−CD15+ subset with neu-
trophil morphology; only a very small population of the
CD11b+CD33+HLA-DRlo/-CD14+CD15− monocytic sub-
set could be identified in the patients’ SF samples. There is
an ongoing debate about an association between pheno-
type and function, as both granulocytic and monocytic
MDSCs have been reported to exhibit immune suppres-
sion in a disease- and tissue site-dependent manner
[12,28]. Moreover, within the granulocytic subset, sup-
pressive cells have been identified among both “immature”
neutrophils (with band-shaped nuclei) and mature neutro-
phils (with segmented or even hyper-segmented nuclei) in
humans [29]. As we described earlier, SF cells harvested
from the arthritic joints of mice with PGIA were also
dominated by granulocytic cells with neutrophil morph-
ology, and these SF cells retained their immune suppres-
sive potential after removal of the minor monocytic
MDSC subset [21]. In the collagen-induced mouse model
of RA, granulocytic MDSCs isolated from the spleens of
arthritic mice suppressed T-cell proliferation in vitro, and
reduced the severity of joint inflammation upon adoptive
transfer in vivo [27]. Taken together, these observations
and our findings described in this study suggest that im-
mune suppressive cells with the phenotypic and morpho-
logic characteristics of neutrophils are present in the SF of
RA patients.
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[21], we found that SF cells from RA patients were much
more potent in suppressing Ag-specific than anti-CD3/
CD28-induced proliferation of autologous T cells. How-
ever, unlike mouse SF cells, SF MDSCs from RA patients
were also able to exert a significant inhibitory effect on
the vigorous proliferation of anti-CD3/CD28-stimulated
T cells. These observations implicate SF MDSCs as non-
selective suppressors of T-cell expansion, and also sug-
gest that the difference in suppressive potency observed
in the Ag-specific versus non-specific systems might
simply be due to the difference in the magnitude of the
response of T cells to these stimuli.
The mechanisms of MDSC-mediated suppression in-
clude depletion of L-arginine by arginase-1, synthesis of
nitric oxide (NO) by inducible NO synthase, and pro-
duction of various oxygen radicals [8], all of which can
have negative effects on the cell cycle and CD3-related
signaling in T cells [29]. We found that the primary
mechanism of immune suppression by mouse granulo-
cytic SF cells involved NO production [21]. The limited
amount of patient samples available for this study did
not allow us to investigate the suppressive mechanisms
employed by RA SF cells. However, elevated concentra-
tions of nitrite (formed from NO) have been reported in
the SF of RA patients [30], suggesting the possibility that
NO production is one of the mechanisms SF MDSCs
use to suppress T-cell proliferation.
Myelopoiesis-supporting factors such as GM-CSF, G-
CSF, and IL-6 have been implicated in the induction and
survival of MDSCs [8,17,24,31]. Notably, these growth
factors are present at high levels in the SF of RA patients
[18], thereby providing a milieu in which MDSCs can
thrive. On the other hand, the widely observed “hypo-re-
sponsiveness” of RA SF T cells to mitogenic stimuli (as
compared to the normal responsiveness of blood T cells
from the same patient) [1,32] might, at least in part, be
related to the long-term exposure of T cells to MDSCs
within the joint exudate. Moreover, although CD4+CD25
+FoxP3+ regulatory T cells might be present in RA SF
[5,33], the inflammatory environment greatly reduces
the capacity of these regulatory T cells to inhibit the ac-
tivity and expansion of effector T cells ex vivo or within
the joint [5,34].
In the collagen-induced mouse model of RA, intraven-
ous (systemic) transfer of spleen-derived MDSCs was
followed by a decrease in the number of CD4+ T cells and
reduced arthritis severity in the recipient mice [27]. Con-
versely, in vivo depletion of MDSCs prevented the spon-
taneous resolution of joint inflammation [27]. We propose
that MDSCs present in RA SF, while inflicting collateral
damage to joint tissues, also serve as negative regulators
of local T-cell expansion in an attempt to break the vi-
cious cycle of autoimmunity and inflammation.Conclusions
In this study, we show for the first time that MDSCs are
present in the SF of RA patients. The majority of RA SF
MDSCs exhibits neutrophil phenotype and morphology,
similarly to MDSCs we identified earlier in the SF of
mice with autoimmune arthritis. The suppression medi-
ated by RA SF cells appears to be non-selective as these
MDSCs potently suppress both the anti-CD3/CD28 Ab-
induced and alloAg-induced proliferation of autologous
blood T cells. We suggest that RA SF MDSCs are able to
limit the expansion of joint-infiltrating (and most likely
pathogenic) T cells. This pilot study represents the first
step of investigations into the role of MDSCs (present in
the inflamed joints and perhaps at other sites) in con-
trolling autoimmune T-cell responses in RA.
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